EE9900113A - Vedelad alendronaatpreparaadid - Google Patents

Vedelad alendronaatpreparaadid

Info

Publication number
EE9900113A
EE9900113A EEP199900113A EE9900113A EE9900113A EE 9900113 A EE9900113 A EE 9900113A EE P199900113 A EEP199900113 A EE P199900113A EE 9900113 A EE9900113 A EE 9900113A EE 9900113 A EE9900113 A EE 9900113A
Authority
EE
Estonia
Prior art keywords
alendronate
liquid formulations
formulations
liquid
alendronate liquid
Prior art date
Application number
EEP199900113A
Other languages
English (en)
Other versions
EE03669B1 (et
Inventor
J. Nerurkar Maneesh
A. Hunke William
Ostovic Drazen
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9700541.7A external-priority patent/GB9700541D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of EE9900113A publication Critical patent/EE9900113A/et
Publication of EE03669B1 publication Critical patent/EE03669B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP199900113A 1996-10-04 1997-10-02 Vedelad alendronaatpreparaadid ja nende valmistamismeetod EE03669B1 (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2676596P 1996-10-04 1996-10-04
GBGB9700541.7A GB9700541D0 (en) 1997-01-13 1997-01-13 Liquid alendronate formulation
US3600297P 1997-01-22 1997-01-22
PCT/US1997/015740 WO1998014196A1 (en) 1996-10-04 1997-10-02 Liquid alendronate formulations

Publications (2)

Publication Number Publication Date
EE9900113A true EE9900113A (et) 1999-10-15
EE03669B1 EE03669B1 (et) 2002-04-15

Family

ID=27268667

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900113A EE03669B1 (et) 1996-10-04 1997-10-02 Vedelad alendronaatpreparaadid ja nende valmistamismeetod

Country Status (20)

Country Link
EP (1) EP1007054A4 (et)
JP (1) JP2001501222A (et)
CN (1) CN1238691A (et)
AU (1) AU723357B2 (et)
BG (1) BG103306A (et)
BR (1) BR9712197A (et)
CA (1) CA2267370A1 (et)
CZ (1) CZ116999A3 (et)
EA (1) EA001213B1 (et)
EE (1) EE03669B1 (et)
HU (1) HUP0000125A3 (et)
IL (1) IL129127A0 (et)
IS (1) IS5012A (et)
NO (1) NO991569L (et)
NZ (1) NZ334836A (et)
PL (1) PL332496A1 (et)
SK (1) SK42999A3 (et)
TR (1) TR199900730T2 (et)
WO (1) WO1998014196A1 (et)
YU (1) YU17499A (et)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002058708A1 (en) 2001-01-23 2002-08-01 Gador S.A. Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof
US20080286359A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080287400A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7473684B2 (en) 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
AU2006290519B2 (en) * 2005-09-16 2012-10-18 Selamine Ltd Bisphosphonate formulation
JP2010043119A (ja) * 2009-10-16 2010-02-25 Gador Sa 骨の代謝病の予防および／または治療のための組成物、その組成物の調製方法およびその使用
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206209A (en) * 1978-11-02 1980-06-03 Kracauer Paul Sublingual aspirin tablet
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US5510517A (en) * 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy

Also Published As

Publication number Publication date
NO991569D0 (no) 1999-03-30
CZ116999A3 (cs) 1999-09-15
IS5012A (is) 1999-03-26
EE03669B1 (et) 2002-04-15
AU723357B2 (en) 2000-08-24
EP1007054A1 (en) 2000-06-14
BR9712197A (pt) 1999-08-31
EA199900352A1 (ru) 1999-08-26
IL129127A0 (en) 2000-02-17
WO1998014196A1 (en) 1998-04-09
EP1007054A4 (en) 2000-07-19
HUP0000125A2 (hu) 2000-06-28
EA001213B1 (ru) 2000-12-25
YU17499A (en) 1999-11-22
SK42999A3 (en) 2000-01-18
TR199900730T2 (xx) 1999-07-21
BG103306A (en) 2000-01-31
CN1238691A (zh) 1999-12-15
NZ334836A (en) 2000-11-24
NO991569L (no) 1999-06-04
JP2001501222A (ja) 2001-01-30
CA2267370A1 (en) 1998-04-09
AU4644897A (en) 1998-04-24
PL332496A1 (en) 1999-09-13
HUP0000125A3 (en) 2001-04-28

Similar Documents

Publication Publication Date Title
DK0853945T3 (da) Flydende gonadotropinholdige formuleringer
NO20001631L (no) 2-metyl-tieno-benzodiazepin formulering
DE69715421D1 (de) Konzentrierte flüssige mikrobizid-enthaltende zusammensetzungen
MA24473A1 (fr) Formulations
DE69732239D1 (de) Flüssige fettverbindung enthaltende zusammensetzung
DE69836513D1 (de) Thermooptische Vorrichtungen
NO985294D0 (no) Kontrastmidler
DE69710315D1 (de) Flüssigkristall-reinigungsmittel
DE29601918U1 (de) Flüssigkeitsspender
NO983828D0 (no) Kontrastmiddel
DE59711705D1 (de) Neue insektizide formulierungen
EE9900113A (et) Vedelad alendronaatpreparaadid
ITMI951395A0 (it) Formulazioni di f-silicone
ID16781A (id) Formulasi-formulasi farmasi
ID20565A (id) Penuntun cairan-cairan secara terus-menerus
DE29716201U1 (de) Anschlußeinrichtung
DE59601357D1 (de) Neue Flüssigformulierungen
DE29614654U1 (de) Tropfenfänger
DE69801367T2 (de) Verbindungsvorrichtung
DE69916615D1 (de) Flüssigformulierung
DE29719479U1 (de) Anschlußeinrichtung
NO991430L (no) Insektfordrivende formuleringer
DE69709700T2 (de) Kontrastmittel
DE29707930U1 (de) Anschlußeinrichtung
ID22385A (id) Formulasi-formulasi alendronat cair

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

MM4A Lapsed by not paying the annual fees

Effective date: 20031002